search
Back to results

Paresthesia Free Spinal Cord Stimulation (PF-SCS)

Primary Purpose

SCS, Chronic Pain

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
PF-SCS programming
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for SCS

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject will be 18-80 years old
  • Subject who is currently treated with PF-SCS (HF-10 or Burst-mode capable SCS system) for chronic pain

Exclusion Criteria:

  • Subject has neurological disease or a condition causing chronic persistent sensory deficit to the painful area
  • Those receiving remuneration for their pain treatment (pending litigation or ongoing litigation).
  • Those unable to read English and complete the assessment instruments.

Sites / Locations

  • MGH Center for Translational Pain ResearchRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Pain Returns

No Pain

Arm Description

PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain returns after switching to the LAP will be considered Group 1.

PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain does not return after switching to the LAP will be considered Group 2.

Outcomes

Primary Outcome Measures

20% increase of NRS (numerical rating scale) pain scale
20% increase on low back pain NRS pain scale (0 = no pain and 10= maximum pain imaginable) while on LAP (lowest amplitude program) compared to OPP (optimal program).

Secondary Outcome Measures

Quantitative Sensory Testing (QST) Results
Compare sensory perception on both the area of pain and the non-painful area on the opposite side while on the OPP (optimal program) and the LAP (lowest amplitude program). The following tests will be analyzed: warm sensation (degrees Celsius) heat pain threshold (degrees Celsius) heat pain tolerance (degrees Celsius) wind-up (NRS pain scale)
Daily diary results
Subject reported responses regarding their pain while using the OPP (optimal program): global impression of change in pain (0=no pain, 10=worst pain) impact on sleep and mood (0= does not interfere, 10= interferes completely) daily living (0= does not interfere, 10= interferes completely) enjoyment and general activity (0= does not interfere, 10= interferes completely)

Full Information

First Posted
August 1, 2018
Last Updated
April 6, 2022
Sponsor
Massachusetts General Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03670147
Brief Title
Paresthesia Free Spinal Cord Stimulation (PF-SCS)
Official Title
Effects of Paresthesia Free Spinal Cord Stimulation on Pain Intensity, Functional Improvement, Pain Thresholds and Sensory Perceptions in Chronic Pain Patients
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2018 (Actual)
Primary Completion Date
September 1, 2022 (Anticipated)
Study Completion Date
December 15, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal is to document efficacy of PF-SCS therapy in a blinded fashion and better understand how SCS therapy works in the clinical setting. Overall the investigators hope to improve patient care and selection of candidates who have the best potential for effective pain relief from an expensive and invasive therapy.
Detailed Description
The PF-SCS has 3 programs (P1, P2, P3) that can be used. At Visit 1, the study physician will review the PF-SCS program that the participant has been using. This program is known as the optimal program (OPP) and will be known as P1. The study physician will then designate the other two programs (P2 and P3); one of them will be identical to the OPP (P1) and the other program will be the LAP. The participant will be unaware if the LAP is assigned to P2 or P3. At the end of Visit 1, the study physician will have the participant switch from P1 to the LAP (P2 or P3). The participant will be reassured that if their pain returns after they switch programs, they can immediately call the study physician and will be switched back to the previous OPP (P1) without delay. The participants whose pain returns will be categorized as Group 1. The physician will document the time that had elapsed before their pain returned. This time will be considered as "carry over time" (COT) from PF-SCS. Only the study physicians will be aware of the programming parameters for P2 and P3. The rest of the study staff and participants will be blinded and will not be aware of the programming parameters for P2 and P3. The participants whose pain remains stable while on the LAP will be categorized as Group 2. All participants will keep a daily diary for pain intensity, sleep and any other concerns that may arise related to the change of program. At the end of Visit 1, a member of the study team will schedule Visit 2, between 14 to 28 days from Visit 1. Phone call: A study physician will call subjects between 7-14 days after Visit 1. Group 1 participants will be asked to switch to the LAP (P2 or P3) before Visit 2. To minimize the duration of the LAP, Visit 2 will be scheduled within six hours from the end of COT. The Group 2 participants will attend Visit 2 without changing their LAP. At Visit 2, participants will fill out questionnaires on pain intensity, sleep, activities and global impression. A blinded study staff will perform QST on the subject. At the end of Visit 2, Group 1 participants will be instructed to go back to the OPP (P1). At the end of Visit 2, Group 2 will be allowed to switch back to the OPP (P1). The investigators will use quantitative sensory testing (QST) as a tool to objectively quantify the impact of SCS on heat pain threshold, heat pain tolerance and wind-up over the painful area and compare this with a non-painful area in each subject. QST will be performed at Visit 1 and Visit 2.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
SCS, Chronic Pain

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Masking Description
The participant and study staff will be blinded. The study physicians will not be blinded.
Allocation
Randomized
Enrollment
68 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Pain Returns
Arm Type
Experimental
Arm Description
PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain returns after switching to the LAP will be considered Group 1.
Arm Title
No Pain
Arm Type
Experimental
Arm Description
PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain does not return after switching to the LAP will be considered Group 2.
Intervention Type
Device
Intervention Name(s)
PF-SCS programming
Intervention Description
In a blinded fashion, the study physician will ask subjects to switch their PF-SCS to the LAP.
Primary Outcome Measure Information:
Title
20% increase of NRS (numerical rating scale) pain scale
Description
20% increase on low back pain NRS pain scale (0 = no pain and 10= maximum pain imaginable) while on LAP (lowest amplitude program) compared to OPP (optimal program).
Time Frame
from date of consent until end of study (14-28 days)
Secondary Outcome Measure Information:
Title
Quantitative Sensory Testing (QST) Results
Description
Compare sensory perception on both the area of pain and the non-painful area on the opposite side while on the OPP (optimal program) and the LAP (lowest amplitude program). The following tests will be analyzed: warm sensation (degrees Celsius) heat pain threshold (degrees Celsius) heat pain tolerance (degrees Celsius) wind-up (NRS pain scale)
Time Frame
from date of consent until end of study (14-28 days)
Title
Daily diary results
Description
Subject reported responses regarding their pain while using the OPP (optimal program): global impression of change in pain (0=no pain, 10=worst pain) impact on sleep and mood (0= does not interfere, 10= interferes completely) daily living (0= does not interfere, 10= interferes completely) enjoyment and general activity (0= does not interfere, 10= interferes completely)
Time Frame
from date of consent until end of study (14-28 days)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject will be 18-80 years old Subject who is currently treated with PF-SCS (HF-10 or Burst-mode capable SCS system) for chronic pain Exclusion Criteria: Subject has neurological disease or a condition causing chronic persistent sensory deficit to the painful area Those receiving remuneration for their pain treatment (pending litigation or ongoing litigation). Those unable to read English and complete the assessment instruments.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Karina de Sousa
Phone
617-724-6102
Email
kdesousa1@mgh.harvard.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Grace Mogren
Phone
617-724-6102
Email
gmogren@mgh.harvard.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shihab Ahmed, M.D.
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
MGH Center for Translational Pain Research
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karina de Sousa
Phone
617-724-6102
Email
kdesousa1@mgh.harvard.edu
First Name & Middle Initial & Last Name & Degree
Grace Mogren
Phone
617-724-6102
Email
gmogren@mgh.harvard.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Paresthesia Free Spinal Cord Stimulation (PF-SCS)

We'll reach out to this number within 24 hrs